# **30-Day Results of the C-GUARDIANS Pivotal Trial of the C-Guard Carotid Stent System**

### **The C-GUARDIANS Trial**

D. Christopher Metzger, MD OhioHealth Riverside Methodist Hospital Columbus, Ohio, USA On Behalf of the C-GUARDIANS Investigators



### **Disclosure Statement of Financial Interest**

### Symposia Honoraria & Proctor Fees:

• Abbott, Endologix

### Symposia Honoraria:

• Boston Scientific, Medtronic, Penumbra, Shockwave

### **VIVA Board Member**

### National PI/Co-PI:

 C-GUARDIANS, CONFIDENCE, SAPPHIRE WW, CANOPY, PERFORMANCE 3

### Stock Options: INSPIREMD

Research Grants, Stocks, Equity: None



# Background

- Goal is carotid artery stenting (CAS) performed at *low* risk of peri-procedural stroke
- More recent CAS trials have shown significant improvement in results, with 30-day stroke and death rates of ~2-3.5%\*
- US : CMS requires use of embolic protection devices, which decrease but do not completely obviate procedural and periprocedural embolic events
- Stents with additional "neuro-protective properties" may further decrease peri-procedural stroke events

\*PROTECT, ARMOUR, EMBOLDEN, CREST 2 Registry (Matsumura, J et al JVS 2012; White, C. et al JACC 2022)





### **<u>POST-CAS Strokes: Advantage for a Micro-Mesh Stent Design?</u>**

#### Approximately 2/3 of Events Occur AFTER the CAS Procedure

Table 6. Over			e Cell Area Influ el red to the differe			e in Carotid Ar	tery Stent	ing?	139
	Total population		Symptomatic population			Asymptomatic population			
	Patients	All events	Post-procedural events	Patients	All events	Post-pricedural events	Patients	All events	Post-procedura events
Free cell area									
$<2,5 \text{ mm}^2$	2107	48	26	882	20	11	1225	28	15
$2,5-5 \text{ mm}^2$	135	3	3	52	1	1	83	2	2 3
$5-7,5 \text{ mm}^2$	327	16	11	155	10	8	172	6	3
$>7,5 \text{ mm}^2$	610	23	21	228	17	16	382	6	5 25
Total	3179	90	61	1317	48	36	1862	42	25
Free cell area									
$<2,5 \text{ mm}^2$		2.3%	1.2%		2.3%	1.2%		2.3%	1.2%
$2,5-5 \text{ mm}^2$		2.2%	2.2%		1.9%	1.9%		2.4%	2.4%
$5-7,5 \mathrm{mm}^2$		4.9%	3.4%		6.5%	5.2%		3.5%	1.7%
$>7,5 \text{ mm}^2$		3.8%	3.4%		7.5%	7.0%		1.6%	1.3%
Total	3179	2.83%	1.9%	1.17	3.6%	2.73%	1862	2.25%	1.3%

#### 40-80% of CAS embolic events are post-procedural





#### Materials and Methods

ous carotid revascularization of the internal carotid artery in the Department of Vascular Surgery of the AZ St-Blasius in Dendermonde, Belgium, in the Department of Cardiovascular and Thoracic Surgery of the Imelda Hospital in Bonheiden, Belgium, in the Department of Vascular and Endovascular Sur gery, University of Siena, Italy, and in the Interventional

1078-5884 /000135 ±07 \$32.00/0 © 2006 Elsevier Ltd. All rights reserved

responding author. M. Bosiers, MD, Department of Vascular erv. AZ St-Blasius. Knonveidlaan 50, 9200 Dendermonde.

terectomy (CEA) the complete plaque is removed

With carotid stenting the plaque remains contained in between the stent and the vessel wall. The stent


needs to offer sufficient scaffolding in order to pre-vent post-procedural plaque embolization through

the stent struts. Logically stents with a smaller free

E-mail address: marc bosiers@telenet.be

Patients 3281 patients were scheduled to undergo percutane

### **Stroke Prevention Strategy: MicroNet Technology**




Conventional Open Cell Stent (1<sup>st</sup> GEN): Bare or dual layer approach, with plaque protrusion risk

#### CGuard Stent System (3<sup>rd</sup> GEN): Stents are covered in MicroNet

D. Christopher Metzger, MD

Important Note: The C-GUARD stent is an *investigational device ONLY* in the US


### "Pore Size" Comparisons of Carotid Stents






### **Theoretic Advantages of CGuard Stent**

- Maximized conformability suitable for more carotid anatomies ("open –cell" stent with proprietary "Smart Fit" auto-taper technology)
- Coupled with maximized *scaffolding and plaque coverage* with smallest pore size and free cell area of available carotid stents
- Potential to minimize plaque protrusion/embolization during procedure at highest risk intervals (stent placement, post dilatation) and post - procedure



#### Images courtesy of Piotr Musialek, MD



# **C-GUARDIANS US Pivotal IDE Trial**

### <u>Disclaimers:</u>

- CE Mark Approved Europe 2015
- INVESTIGATIONAL Only in US
  - In C-GUARDIANS IDE Trial (enrollment completed), and allowed as part of ongoing CREST 2 trial
- Results presented today are 30- day results, although the primary endpoint for the trial is a 1-year composite endpoint
  FDA approved this 30- day result presentation



C-GUARDIANS Study Design	Prospective, multicenter, single- armed IDE Pivotal trial
Sample size/ Sites	316 Patients; 25 US and European Sites
Primary Endpoint	Composite of death, stroke, MI (DSMI) at 30 days or ipsilateral stroke at 1 year
Sponsor	INSPIRE MD
Principal Investigator Co- Principal Investigator	D. Chris Metzger, MD Piotr Musialek, MD
Study Enrollment Period	July, 2021 to June, 2023 (23 months)
Monitor/ CRO	Hart Clinical Consultants



# **Other Key Study Personnel**

Clinical Trial Executive	Christina Brennan, MD, MBA
Angiographic and Duplex Core Lab	Syntropic; Raghu Kolluri, MD
DSMB	Chair: Gary Ansel, MD
CEC (adjudicated all cardiac & neuro events)	Chair: Mark Burket, MD
Senior Clinical Manager	Mena Shiano Lo Moriello
Screening Committee	Chair: Bruce Gray, DO
Hart Global Project Manager	Patricia Ayers

V

25



### 25 investigative sites in the US and Europe

- Ascension Seton Heart (UT Austin)
- Asklepios Hospital St Georg
- Avera Heart Hospital (NC Heart)
- Ballad Wellmont Holston Valley
- Baylor Plano
- Brookwood Baptist
- Cleveland Clinic
- Columbia Medical Center
- Imland Klinik Rendsburg
- John Paul II Hospital
- Mercy Heart & Vascular
- Miriam Hospital
- Novant Health/Forsyth MC

- Ochsner
- Prairie Research
- Prisma Health
- Silesian Medical University
- St. John's
- SUNY Stony Brook UMC
- Tennova Healthcare
- UNC Heart & Vascular
- University of Buffalo
- University of Florida
- University of Leipzig
- UPMC Pinnacle

# **Study Patients**

- Patients  $\leq$  80 years of age at high risk for carotid endarterectomy
- Asymptomatic  $\geq$  80%, symptomatic  $\geq$  50% stenosis
  - Pre-specified 25% of population symptomatic per FDA
- All patients had pre-CAS carotid duplex and CTA/MRA
- All patients were approved by screening committee (2 approvals)
- All patients required to have embolic protection with Abbott Emboshield NAV 6, MoMa proximal embolic protection, or both
- All neurologic and cardiac events adjudicated by CEC



## **Study Visits and Evaluations**

Pre- Procedure	NIHSS, CDU, CTA
Post CAS, Discharge or 96 hours	NIHSS, Clinical events
30 Days Post CAS	NIHSS, CDU, Clinical exam and events
6 months post CAS	NIHSS, CDU, Clinical exam and events
1 year	NIHSS, CDU, Clinical exam and events
2 year	NIHSS, CDU, Clinical exam and events
3 year	NIHSS, CDU, Clinical exam and events



# **Patient Demographics**

Characteristic	ITT (N = 316)		
Age (mean ± SD)	69.0 ± 6.6		
% Symptomatic	24.3%		
% Male	63.9%		
Diabetes Mellitus	41.8%		
Hypertension	92.6%		
Dyslipidemia	90%		
CAD	52.1%		
COPD	23.8%		
Current Smoker	26.4%		
PVD	28.6%		

23,

V

V



# **Embolic Protection Utilized**

Emboshield NAV 6 Distal embolic protection	261
MoMA Proximal embolic protection	78
Both (Nav6 and MoMa)	24
None	1

V

# **C-GUARDIANS 30-day Results**

ITT Analysis (N = 316)	Event rate in % (n)		
Death, Stroke or MI*	0.95%(3)		
Death <sup>#</sup>	0.32% (1)		
Any stroke <sup>#</sup>	0.95% (3)		
Major Stroke <sup>#</sup>	0.63% (2)		
Minor Stroke <sup>#</sup>	0.32% (1)		
MI	0.0% (0)		
Death or any stroke <sup>*</sup>	0.95% (3)		
Death or major stroke <sup>*</sup>	0.63% (2)		

\* Hierarchical: patient count (each patient first occurrence of the most serious event).

# Non-hierarchical: event count (multiple events in each patient are counted individually).

### **C-Guardians: 30-day Major Adverse Events**

The CEC independently adjudicated all neurological, cardiac events:

- 1 major fatal stroke on post procedural day 10 after all DAPT stopped contrary to per protocol requirements.
- 1 major stroke. (NIHSS 2, post procedure). NIHSS 1, CDU patent 30 days, NIHSS 0 at 6 and 12 months
- 1 retinal infarct in a patient presenting with amaurosis fugax, adjudicated as a minor stroke. (NIHSS 1). NIHSS 0, CDU patent 30 days

CGuard Stent system is investigational only and not for sale in the USA.

### **C-Guardians: 30-day Major Adverse Events**

Event rate in % (n)	ITT (N=316)	Per Protocol <sup>^</sup>
Death, Stroke or MI*	0.95% (3)	0.63% (2)
Death <sup>#</sup>	0.32% (1)	0.% (0)
Any stroke <sup>#</sup>	0.95% (3)	0.63% (2)
Major Stroke <sup>#</sup>	0.63% (2)	0.32% (1)
Minor Stroke <sup>#</sup>	0.32% (1)	0.32% (1)
MI#	0.0% (0)	0.0% (0)
Death or any stroke*	0.95% (3)	0.63% (2)
Death or major stroke*	0.63% (2)	0.32% (1)

\* Hierarchical: patient count (each patient first occurrence of the most serious event).

<sup>#</sup> Non-hierarchical: event count (multiple events in each patient are counted individually).

^ Per Protocol Analysis excludes 1 patient (did not take dual antiplatelet therapy; had a major stroke and died).

CGuard Stent system is investigational only and not for sale in the USA



# Conclusions

- In the C-GUARDIANS IDE Pivotal trial of patients at high risk for carotid endarterectomy with obstructive carotid disease (25% symptomatic), treatment with carotid artery stenting with the CGuard carotid stent system with embolic protection had a low incidence of stroke, death, or MI post-procedure to 30 day follow up
- These results appear to confirm a potential "neuro-protective" effect of this stent
- We await the pre-specified 1- year primary composite endpoint results of this trial

Event Rate in % (n)	ITT	Per Protocol
Death/ Stroke/ MI	0.95%	0.63%
Death/ Stroke	0.95%	0.63%



### Thank You for Your Attention!



V I V A 23